Hepatitis C  >>  Isentress (raltegravir)  >>  Phase 2
Welcome,         Profile    Billing    Logout  

3 Trials

Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Isentress (raltegravir) / Merck (MSD)
NCT01231685: Raltegravir Switch Study to Reduce Liver Fibrosis Progression in HIV-Hepatitis C Co-infection

Completed
2
9
Canada
Raltegravir, Isentress, MK-0518, RGV, Ritonavir-boosted protease inhibitor, Kaletra, Lopinavir-ritonavir, Atazanavir-ritonavir, Reyataz-norvir, Darunavir-ritonavir, Presista-norvir
McGill University Health Centre/Research Institute of the McGill University Health Centre, Merck Sharp & Dohme LLC, CIHR Canadian HIV Trials Network
HIV, Hepatitis C, Liver Fibrosis
03/16
09/16
LIVERAL, NCT01022476 / 2009-014616-36: Raltegravir in Patients With End Stage Liver Disease and in Transplant Recipients

Completed
1/2
14
Europe
Raltegravir potassium, ISENTRESS
ANRS, Emerging Infectious Diseases, Merck Sharp & Dohme LLC
HIV Infection, Liver Failure, Evidence of Liver Transplantation
05/13
05/13
NCT01565889: Part A: Drug Interaction Study of Sofosbuvir and Antiretroviral Therapy (ART) Combinations in HIV and Hepatitis C Virus (HCV) Co-infected Patients. Part B: Efficacy and Safety of Sofosbuvir for 12 Weeks in HIV/HCV Co-infected Patients.

Completed
1/2
52
US
SOF, Sovaldi®, GS-7977, PSI-7977, EFV/FTC/TDF, Atripla®, EFV, Sustiva®, ZDV/3TC, Combivir®, ATV, Ritonavir, FTC/TDF, Truvada®, DRV, RAL, PEG, Pegasys®, RBV, Ribasphere®
Gilead Sciences
Hepatitis C, HIV
08/13
11/13

Download Options